by Communication Team | Mar 22, 2021 | ODYSSEY
As the world continues to raise its voice towards improving HIV treatment in children , the contributions made by the ODYSSEY trial have not gone unnoticed and as a result, has earned researchers the Radboud Institute for Health Sciences Societal Impact...
by Communication Team | Mar 11, 2021 | ODYSSEY
The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug anti-HIV combination. These results come from the ODYSSEY trial which was presented yesterday at the Conference on Retroviruses and Opportunistic Infections....
by Communication Team | Feb 17, 2021 | ODYSSEY
UNIVERSAL, the newly funded European-African clinical research partnership will develop, evaluate and register two new antiretroviral formulations for infants and children newly diagnosed with HIV initiating antiretroviral therapy, and for children failing...
by Communication Team | Jan 21, 2021 | ODYSSEY
On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe. This decision was based, in part, on data from our ODYSSEY trial, which we are conducting in close...
by Communication Team | Dec 21, 2020 | ODYSSEY
With the world engulfed by the COVID-19 pandemic, you may not have heard about some of the breakthroughs that the scientific community has made in the treatment of paediatric HIV. One such breakthrough is the development of dispersible dolutegravir. Find more on...
by Communication Team | Nov 19, 2020 | ODYSSEY
On November 12th, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorisation for dolutegravir 5mg dispersible tablets for young children living with HIV. This decision...
Recent Comments